EP300 and invasive breast carcinoma: Compared to the corresponding normal tissues, EP300-AS1 expression was significantly decreased in SCLC tissues, whereas no significant differences in EP300-AS1 expression were observed in colon adenocarcinoma (COAD), stomach adenocarcinoma (STAD), liver hepatocellular carcinoma (LIHC), breast carcinoma (BRCA), or kidney renal clear cell carcinoma (KIRC) (Fig. S8a).